comparemela.com

Latest Breaking News On - Webcast today - Page 12 : comparemela.com

HUTCHMED Reports 2023 Interim Results and Provides Business Updates - HUTCHMED (China) (NASDAQ:HCM)

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to

Shanghai
China
Macau-special-administrative-region
Macau-general
Macau
United-states
Hong-kong
Hainan
Japan
Japanese
Weiguo-su
Astrazeneca

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% to US$533 million, with net.

Japan
China
Macau
Macau-special-administrative-region
Macau-general
Hong-kong
Hainan
Shanghai
United-states
Japanese
American
Zhou-yi

NLS Pharmaceutics Company Update and Webcast Today Postponed

NLS Pharmaceutics Company Update and Webcast Today Postponed
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

Switzerland
Zurich
Züsz
Swiss
Updatecorporate-developmentwebcast
Marianne-lambertson
Nasdaq
Pharmaceutics-company
Leadership-team
Pharmaceutics-ltd
News-network
Company-update

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
Cambridge
Cambridgeshire
United-kingdom
Israel
United-states
American
Jonathan-solomon
Michaele-dambach
Michael-dambach
John-mullaly
Biogen-inc

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy ; On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to. | May 11, 2023

San-diego
California
United-states
Japan
Joyce-allaire
Linda-marb
Raquel-cona
Nasdaq
Exosome-platform-technology
Capricor-therapeutics-inc
Twitter
Nippon-shinyaku-co-ltd

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.